XPAD European Feasibility Study

Starting soon · Not applicable

Conditions studied: Peripheral Arterial Disease

In brief

A prospective, single arm, non-randomized European feasibility study to evaluate the safety and performance of the XPAD conduit in patients with peripheral arterial occlusive disease (PAOD), scheduled to undergo elective lower-limb, above or below the knee, bypass surgery.

Key facts

Study ID

NCT07716020

Run by

Xeltis

People needed

15

Starts

2026-12-01

Expected to finish

2032-12-01

Last updated by the study team

2026-07-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants with peripheral artery occlusion who require elective lower-limb bypass surgery
• Participant has Rutherford grade 3 or 4 occlusive vascular disease and TASC C or D lesions.
• At least 18 years of age at screening
• Suitable anatomy while avoiding joints (assessed by a pre-procedural contrasted CT scan or previous angiogram assessed up to 90 days prior to baseline)
• Participant has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent
• Participant has been informed and agrees to pre- and post-procedure follow-up, including follow-up angiography
• Life expectancy of at least 24 months

You may not qualify if…

• Participant requires, or is scheduled for, a cardiac surgical procedure or a different vascular surgical procedure within 30 days of study procedure.
• Stroke or myocardial infarction event within 6 weeks of the procedure or evidence of prior massive stroke (Modified Rankin Scale 3 or above)
• History of acute arterial occlusion requiring an emergent intervention within the last 12 months
• Severe chronic renal insufficiency (serum creatinine >2.5 mg/dL) or undergoing hemodialysis
• Previous renal transplant
• Uncontrolled arterial hypertension (BP >200 mmHg) at 2 successive readings
• Uncontrolled or poorly controlled diabetes
• Abnormal blood values that could influence participant recovery and or/ graft hemostasis
• Reduced liver function, defined as: >2x the upper limit of normal for serum bilirubin, International Normalized Ratio (INR) >1.5 or prothrombin time (PT) >18 seconds
• Any active local or systemic infection
• Known heparin- induced thrombocytopenia, active bleeding disorder and/or any coagulopathy or thromboembolic disease
• Allergies to study device (nitinol) or agents/medication, such as contrast agents, aspirin or NOACs, that can't be controlled medically
• Previous enrolment in this study
• Participant is participating in another study
• Pregnant or breastfeeding woman or woman in fertile period not taking adequate contraceptives
• Any other condition which, in the judgement of the investigator would preclude adequate evaluation for the safety and performance of the study conduit
• Intra-operative exclusion criteria:
• Unsuitable anatomy to implant the XPAD conduit (e.g. target vessel diameter smaller than anticipated; severe calcification)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.